Business
LIXTE Biotechnology (LIXT) Aligns Liora and LiGHT System With LB-100 to Push Frontier of Cancer Treatment
LOS ANGELES, CA - February 10, 2026 (NEWMEDIAWIRE) - LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, a company that's pioneering proton therapy systems for treating tumors in...
About this update from Lixte Biotechnology Holdings, Inc.
[{"type":"text","content":"LOS ANGELES, CA - February 10, 2026 (NEWMEDIAWIRE) - LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, a company that's pioneering proton therapy systems for treating tumors in various types of cancers.","length":280,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"LIXTE Biotechnology recently acquired Liora Technologies, and the acquisition includes Liora's proprietary LiGHT system","length":123,"tagName":"p"}]},{"val":[{"type":"text","content":"This system provides several advantages over technologies that are currently available for treating tumors with proton therapy","length":126,"tagName":"p"}]},{"val":[{"type":"text","content":"The LiGHT system also complements LIXTE's LB-100, which is the company's lead clinical candidate that's designed to help boost the activity of both chemotherapy and immunotherapy","length":190,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":439,"olType":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"Investor Brand Network","className":"","disableSlideshowImg":false,"size":{"original":{"width":1293,"height":507,"url":"https://media.zenfs.com/en/newsmediawire_165/24e5e865c170c2b5e9a7a0400b575fd2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VCVJ6yC337nqarY7rX_X7Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM3NjtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/24e5e865c170c2b5e9a7a0400b575fd2","width":960,"height":376},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/MmFuzfq1hlGGX6FrBtdqXg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05NDI7Y2Y9d2VicA--/https://media.zenfs.com/en/newsmediawire_165/24e5e865c170c2b5e9a7a0400b575fd2","width":1200,"height":471}}},{"type":"text","content":"Liora is becoming a wholly owned subsidiary of LIXTE, and the acquisition also includes Liora's proprietary flagship technology, the LiGHT System (Linac for Image Guided Hadron Therapy), which offers many advantages over other technologies that are currently available for treating tumors with","length":297,"tagName":"p"},{"type":"text","content":"Read More","length":9,"tagName":"p"},{"type":"text","content":"Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever publishe...